<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CISPLATIN- cisplatin injection </strong><br>Mylan Institutional LLC <br></p></div>
<h1>Cisplatin Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID1"></a><a name="section-1"></a><p></p>
<p class="First"><a name="ID2"></a><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="ID3"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><a name="ID4"></a>Cisplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. </p>
<p>Cumulative renal toxicity associated with Cisplatin injection is severe. Other major dose-related toxicities are <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>, which may be more pronounced in children, and is manifested by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and/or loss of high frequency hearing and occasionally <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, is significant. </p>
<p><span class="Italics">Anaphylactic-like </span>reactions to Cisplatin injection have been reported. Facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur within minutes of Cisplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been effectively employed to alleviate symptoms (see <span class="Bold"><a href="#ID22">WARNINGS</a></span>and <span class="Bold"><a href="#ID36">ADVERSE REACTIONS </a></span>sections). </p>
<p><span class="Bold">Exercise caution to prevent inadvertent Cisplatin injection <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </span>Doses greater than 100 mg/m<span class="Sup">2</span>/cycle once every 3 to 4 weeks are rarely used. Care must be taken to avoid inadvertent Cisplatin injection <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> due to <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID5"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="ID6"></a>Cisplatin injection infusion concentrate is a clear, colorless, sterile aqueous solution available in amber vials. Each 50 mL or 100 mL amber vial of infusion concentrate contains: 1 mg/mL cisplatin, 9 mg/mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection to a final volume of 50 mL or 100 mL, respectively. The pH range of Cisplatin Injection is 3.5 to 6.5.</p>
<p>Cisplatin injection infusion concentrate must be further diluted prior to administration (see <span class="Bold"><a href="#ID63">DOSAGE AND ADMINISTRATION</a>: <a href="#ID71">All Patients</a></span>).</p>
<p>The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl<span class="Sub">2</span>H<span class="Sub">6</span>N<span class="Sub">2</span>, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207° C.            </p>
<div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb&amp;name=cisplatininjmylan-figure-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID8"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="ID9"></a>Plasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 or 100 mg/m<span class="Sup">2 </span>doses. Monoexponential decay and plasma half-lives of about 0.5 hour are also seen following 2-hour or 7-hour infusions of 100 mg/m<span class="Sup">2</span>. After the latter, the total-body clearances and volumes of distribution at steady-state for cisplatin are about 15 to 16 L/h/m<span class="Sup">2 </span>and 11 to 12 L/m<span class="Sup">2</span>. </p>
<p>Due to its unique chemical structure, the chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism. At physiological pH in the presence of 0.1M NaCl, the predominant molecular species are cisplatin and monohydroxymonochloro <span class="Italics">cis-</span>diammine platinum (II) in nearly equal concentrations. The latter, combined with the possible direct displacement of the chlorine atoms by sulfhydryl groups of amino acids or proteins, accounts for the instability of cisplatin in biological matrices. The ratios of cisplatin to total free (ultrafilterable) platinum in the plasma vary considerably between patients and range from 0.5 to 1.1 after a dose of 100 mg/m<span class="Sup">2</span>.</p>
<p>Cisplatin does not undergo the instantaneous and reversible binding to plasma proteins that is characteristic of normal drug-protein binding. However, the platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.</p>
<p>Following cisplatin doses of 20 to 120 mg/m<span class="Sup">2</span>, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration. With the exception of intracerebral tumors, platinum concentrations in tumors are generally somewhat lower than the concentrations in the organ where the tumor is located. Different metastatic sites in the same patient may have different platinum concentrations. Hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> have the highest platinum concentrations, but these are similar to the platinum concentrations in normal liver. Maximum red blood cell concentrations of platinum are reached within 90 to 150 minutes after a 100 mg/m<span class="Sup">2</span> dose of cisplatin and decline in a biphasic manner with a terminal half-life of 36 to 47 days.</p>
<p>Over a dose range of 40 to 140 mg cisplatin/m<span class="Sup">2</span> given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours. Over five days following administration of 40 to 100 mg/m<span class="Sup">2</span> doses given as rapid, 2- to 3-hour, or 6- to 8-hour infusions, a mean of 35% to 51% of the dosed platinum is excreted in the urine. Similar mean urinary recoveries of platinum of about 14% to 30% of the dose are found following five daily administrations of 20, 30, or 40 mg/m<span class="Sup">2</span>/day. Only a small percentage of the administered platinum is excreted beyond 24 hours post-infusion and most of the platinum excreted in the urine in 24 hours is excreted within the first few hours. Platinum-containing species excreted in the urine are the same as those found following the incubation of cisplatin with urine from healthy subjects, except that the proportions are different.</p>
<p>The parent compound, cisplatin, is excreted in the urine and accounts for 13% to 17% of the dose excreted within one hour after administration of 50 mg/m<span class="Sup">2</span>. The mean renal clearance of cisplatin exceeds creatinine clearance and is 62 and 50 mL/min/m<span class="Sup">2</span> following administration of 100 mg/m<span class="Sup">2</span> as 2-hour or 6- to 7-hour infusions, respectively. </p>
<p>The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption. </p>
<p>There is a potential for accumulation of ultrafilterable platinum plasma concentrations whenever cisplatin is administered on a daily basis but not when dosed on an intermittent basis. </p>
<p>No significant relationships exist between the renal clearance of either free platinum or cisplatin and creatinine clearance.</p>
<p>Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant.</p>
<div class="Section">
<a name="ID10"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacogenomics</h2>
<p class="First"><a name="ID11"></a>Certain genetic variants in the thiopurine S-methyltransferase gene (e.g., TPMT*3B and TPMT*3C) are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> in children administered conventional doses of cisplatin. A retrospective study was conducted in 162 children, the majority of whom were of European ancestry. Patients were administered a median cumulative cisplatin dose of 400 mg/m<span class="Sup">2</span> for a median treatment duration of 4-5 weeks. Of those 162 children, 106 had severe <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> (Grade 2 or greater). Twenty-six of the 162 patients had one or more TPMT gene variants. Of these 26 patients, 25 had severe <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> (96%). For Caucasians and African Americans, approximately 11% of the population inherit one or more of these variants. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID12"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="ID13"></a>Cisplatin injection is indicated as therapy to be employed as follows: </p>
<div class="Section">
<a name="ID14"></a><a name="section-4.1"></a><p></p>
<h2>Metastatic Testicular Tumors</h2>
<p class="First"><a name="ID15"></a>In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.</p>
</div>
<div class="Section">
<a name="ID16"></a><a name="section-4.2"></a><p></p>
<h2>Metastatic Ovarian Tumors</h2>
<p class="First"><a name="ID17"></a>In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy.</p>
</div>
<div class="Section">
<a name="ID18"></a><a name="section-4.3"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span></h2>
<p class="First"><a name="ID19"></a>Cisplatin injection is indicated as a single agent for patients with transitional cell <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> which is no longer amenable to local treatments, such as surgery and/or radiotherapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID20"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="ID21"></a>Cisplatin injection is contraindicated in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Cisplatin injection should not be employed in myelosuppressed patients, or in patients with hearing impairment. </p>
<p>Cisplatin injection is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Cisplatin injection or other platinum-containing compounds.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID22"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="ID23"></a>Cisplatin injection produces cumulative <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> which is potentiated by aminoglycoside antibiotics. The serum creatinine, blood urea nitrogen (BUN), creatinine clearance, and magnesium, sodium, potassium, and calcium levels should be measured prior to initiating therapy, and prior to each subsequent course. At the recommended dosage, Cisplatin injection should not be given more frequently than once every 3 to 4 weeks (see <span class="Bold"><a href="#ID36">ADVERSE REACTIONS</a></span>). Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> (see <span class="Bold"><a href="#ID24">PRECAUTIONS</a>: <a href="#ID34">Geriatric Use</a></span>).</p>
<p>There are reports of severe neuropathies in patients in whom regimens are employed using higher doses of Cisplatin injection or greater dose frequencies than those recommended. These neuropathies may be irreversible and are seen as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> in a stocking-glove distribution, <span class="product-label-link" type="condition" conceptid="4290597" conceptname="Absent reflex">areflexia</span>, and loss of proprioception and vibratory sensation. Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (see <span class="Bold"><a href="#ID24">PRECAUTIONS</a>: <a href="#ID34">Geriatric Use</a></span>).</p>
<p>Loss of motor function has also been reported.</p>
<p>Anaphylactic-like reactions to Cisplatin injection have been reported. These reactions have occurred within minutes of administration to patients with prior exposure to Cisplatin injection, and have been alleviated by administration of epinephrine, corticosteroids, and antihistamines.</p>
<p>Cisplatin injection can commonly cause <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> which is cumulative and may be severe. Audiometric testing should be performed prior to initiating therapy and prior to each subsequent dose of drug (see <span class="Bold"><a href="#ID36">ADVERSE REACTIONS</a></span>). </p>
<p>Certain genetic variants in the thiopurine S-methyltransferase (TPMT) gene are associated with increased risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> in children administered conventional doses of cisplatin (see <span class="Bold"><a href="#ID8">CLINICAL PHARMACOLOGY</a></span>). Children who do not have one of these TPMT gene variants remain at risk for <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>. All pediatric patients receiving cisplatin should have audiometric testing at baseline, prior to each subsequent dose, of drug and for several years post therapy.</p>
<p>Cisplatin injection can cause fetal harm when administered to a pregnant woman. Cisplatin injection is mutagenic in bacteria and produces chromosome aberrations in animal cells in tissue culture. In mice Cisplatin injection is teratogenic and embryotoxic. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should be advised to avoid becoming pregnant.</p>
<p>The carcinogenic effect of Cisplatin injection was studied in BD IX rats. Cisplatin injection was administered intraperitoneally (i.p.) to 50 BD IX rats for 3 weeks, 3 X 1 mg/kg body weight per week. Four hundred and fifty-five days after the first application, 33 animals died, 13 of them related to malignancies: 12 <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and 1 renal <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcoma</span>.</p>
<p>The development of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> coincident with the use of Cisplatin injection has been reported. In these reports, Cisplatin injection was generally given in combination with other leukemogenic agents.</p>
<p><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span> may occur during the administration of Cisplatin injection (see <span class="Bold"><a href="#ID36">ADVERSE REACTIONS</a></span>). Given the possibility of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> reactions is unknown at this time.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID24"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><a name="ID25"></a>Peripheral blood counts should be monitored weekly. Liver function should be monitored periodically. Neurologic examination should also be performed regularly (see <span class="Bold"><a href="#ID36">ADVERSE REACTIONS</a>).</span></p>
<div class="Section" data-sectionCode="34073-7">
<a name="ID26"></a><a name="section-7.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="ID27"></a>Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy. </p>
<p>In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and Cisplatin injection.</p>
</div>
<div class="Section">
<a name="ID28"></a><a name="section-7.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID29"></a>See <span class="Bold"><a href="#ID22">WARNINGS</a></span></p>
<p><span class="Bold">Pregnancy</span></p>
<p><span class="Bold">Pregnancy Category D</span></p>
<p>See <span class="Bold"><a href="#ID22">WARNINGS</a></span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID30"></a><a name="section-7.3"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="ID31"></a>Cisplatin has been reported to be found in human milk; patients receiving Cisplatin injection should not breast-feed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID32"></a><a name="section-7.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="ID33"></a>Safety and effectiveness in pediatric patients have not been established. Variants in the thiopurine S-methyltransferase (TPMT) gene are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> in children treated with cisplatin (see <span class="Bold"><a href="#ID8">CLINICAL PHARMACOLOGY</a>). </span></p>
<p>All children should have audiometric monitoring performed prior to initiation of therapy prior to each subsequent dose, and for several years post therapy. Advanced testing methods may allow for earlier detection of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> in an attempt to facilitate the rapid initiation of interventions that can limit the potential adverse impact of hearing impairment on a child’s cognitive and social development.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID34"></a><a name="section-7.5"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="ID35"></a>Insufficient data are available from clinical trials of cisplatin in the treatment of metastatic testicular tumors or advanced <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> to determine whether elderly patients respond differently than younger patients. In four clinical trials of combination chemotherapy for advanced ovarian carcinoma, 1484 patients received cisplatin either in combination with cyclophosphamide or paclitaxel. Of these, 426 (29%) were older than 65 years. In these trials, age was not found to be a prognostic factor for survival. However, in a later secondary analysis for one of these trials, elderly patients were found to have shorter survival compared with younger patients. In all four trials, elderly patients experienced more severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> than younger patients. Higher incidences of severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> were also seen in elderly compared with younger patients, although not in all cisplatin-containing treatment arms. In the two trials where nonhematologic toxicity was evaluated according to age, elderly patients had a numerically higher incidence of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> than younger patients. Other reported clinical experience suggests that elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, infectious complications, and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> than younger patients.  </p>
<p>Cisplatin is known to be substantially excreted by the kidney and is contraindicated in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID36"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section">
<a name="ID37"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First"><a name="ID38"></a>Dose-related and cumulative <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, is the major dose-limiting toxicity of Cisplatin injection. Renal toxicity has been noted in 28% to 36% of patients treated with a single dose of 50 mg/m<span class="Sup">2</span>. It is first noted during the second week after a dose and is manifested by elevations in BUN and creatinine, serum uric acid and/or a decrease in creatinine clearance. <span class="Bold">Renal toxicity becomes more prolonged and severe with repeated courses of the drug. Renal function must return to normal before another dose of Cisplatin injection can be given. </span>Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> (see <span class="Bold"><a href="#ID24">PRECAUTIONS</a>: <a href="#ID34">Geriatric Use</a></span>).</p>
<p>Impairment of renal function has been associated with renal tubular damage. The administration of Cisplatin injection using a 6- to 8-hour infusion with intravenous hydration, and mannitol has been used to reduce <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. However, renal toxicity still can occur after utilization of these procedures.</p>
</div>
<div class="Section">
<a name="ID39"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></h2>
<p class="First"><a name="ID40"></a><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> has been observed in up to 31% of patients treated with a single dose of Cisplatin injection 50 mg/m<span class="Sup">2</span>, and is manifested by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and/or <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> in the high frequency range (4000 to 8000 Hz). The prevelance of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> in children is particularly high and is estimated to be 40-60%. Decreased ability to hear normal conversational tones may occur. <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span> after the initial dose of Cisplatin injection has been reported. Ototoxic effects may be more severe in children receiving Cisplatin injection. </p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> can be unilateral or bilateral and tends to become more frequent and severe with repeated cisplatin doses. It is unclear whether Cisplatin injection induced <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> is reversible. Vestibular toxicity has also been reported. Ototoxic effects may be related to the peak plasma concentration of cisplatin. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> can occur during treatment or be delayed. Audiometric monitoring should be performed prior to initiation of therapy, prior to each subsequent dose, and for several years post therapy.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> may increased by prior or simultaneous cranial irradiation, and may be more severe in patients less than 5 years of age, patients being treated with other ototoxic drugs (e.g. aminoglycosides and vancomycin), and in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Variants in the thiopurine S-methyltransferase gene (TPMT) have been reported to be associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> in children treated with cisplatin (see <span class="Bold"><a href="#ID8">CLINICAL PHARMACOLOGY</a>). </span></p>
<p>Other genetic factors may also contribute to the cisplatin-induced <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>.</p>
</div>
<div class="Section">
<a name="ID41"></a><a name="section-8.3"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><a name="ID42"></a><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> occurs in 25% to 30% of patients treated with Cisplatin injection. The nadirs in circulating platelets and leukocytes occur between days 18 to 23 (range 7.5 to 45) with most patients recovering by day 39 (range 13 to 62). <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> are more pronounced at higher doses (&gt;50 mg/m<span class="Sup">2</span>). <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (decrease of 2 g hemoglobin/100 mL) occurs at approximately the same frequency and with the same timing as <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> have also been reported in patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Potential fatalities due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (secondary to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>) have been reported. Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (see <span class="Bold"><a href="#ID24">PRECAUTIONS</a>: <a href="#ID34">Geriatric Use</a></span>).</p>
<p>In addition to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> secondary to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, a Coombs' positive <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> has been reported. In the presence of cisplatin <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, a further course of treatment may be accompanied by increased <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and this risk should be weighed by the treating physician. </p>
<p>The development of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> coincident with the use of Cisplatin injection has been reported. In these reports, Cisplatin injection was generally given in combination with other leukemogenic agents.</p>
</div>
<div class="Section">
<a name="ID43"></a><a name="section-8.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><a name="ID44"></a>Marked <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur in almost all patients treated with Cisplatin injection, and may be so severe that the drug must be discontinued. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may begin within 1 to 4 hours after treatment and last up to 24 hours. Various degrees of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> may persist for up to 1 week after treatment. </p>
<p>Delayed <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (begins or persists 24 hours or more after chemotherapy) has occurred in patients attaining complete emetic control on the day of Cisplatin injection therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> has also been reported.</p>
</div>
<div class="Section">
<a name="ID45"></a><a name="section-8.5"></a><p></p>
<h2>OTHER TOXICITIES</h2>
<p class="First"><a name="ID46"></a>Vascular toxicities coincident with the use of Cisplatin injection in combination with other antineoplastic agents have been reported. The events are clinically heterogeneous and may include <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="313800" conceptname="Thrombotic microangiopathy">thrombotic microangiopathy</span> (hemolytic-<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremic syndrome</span> [HUS]), or <span class="product-label-link" type="condition" conceptid="380747" conceptname="Cerebral arteritis">cerebral arteritis</span>. Various mechanisms have been proposed for these vascular complications. There are also reports of Raynaud’s phenomenon occurring in patients treated with the combination of bleomycin, vinblastine with or without Cisplatin injection. It has been suggested that <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> developing coincident with the use of Cisplatin injection may be an added, although not essential, factor associated with this event. However, it is currently unknown if the cause of Raynaud’s phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or a combination of any of these factors.</p>
</div>
<div class="Section">
<a name="ID47"></a><a name="section-8.6"></a><p></p>
<h2>Serum <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></h2>
<p class="First"><a name="ID48"></a><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been reported to occur in patients treated with Cisplatin injection and are probably related to renal tubular damage. <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">Tetany</span> has been reported in those patients with <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Generally, normal serum electrolyte levels are restored by administering supplemental electrolytes and discontinuing Cisplatin injection.</p>
<p>Inappropriate antidiuretic hormone syndrome has also been reported.</p>
</div>
<div class="Section">
<a name="ID49"></a><a name="section-8.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></h2>
<p class="First"><a name="ID50"></a><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> has been reported to occur at approximately the same frequency as the increases in BUN and serum creatinine. </p>
<p>It is more pronounced after doses greater than 50 mg/m<span class="Sup">2</span>, and peak levels of uric acid generally occur between 3 to 5 days after the dose. Allopurinol therapy for <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> effectively reduces uric acid levels.</p>
</div>
<div class="Section">
<a name="ID51"></a><a name="section-8.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></h2>
<p class="First"><a name="ID52"></a>See <span class="Bold"><a href="#ID22">WARNINGS</a></span> </p>
<p><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>, usually characterized by peripheral neuropathies, has been reported. The neuropathies usually occur after prolonged therapy (4 to 7 months); however, <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> have been reported to occur after a single dose. Although symptoms and signs of Cisplatin injection <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> usually develop during treatment, symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> may begin 3 to 8 weeks after the last dose of Cisplatin injection. Cisplatin injection therapy should be discontinued when the symptoms are first observed.</p>
<p>The <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, however, may progress further even after stopping treatment. Preliminary evidence suggests <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> may be irreversible in some patients. Elderly patients may be more susceptible to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (see <span class="Bold"><a href="#ID24">PRECAUTIONS</a>: <a href="#ID34">Geriatric Use</a></span>).</p>
<p>Lhermitte's sign, dorsal column <span class="product-label-link" type="condition" conceptid="135526" conceptname="Spinal cord disease">myelopathy</span>, and <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span> have also been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Loss of taste</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span>, and <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span> (RPLS) have also been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>, defined as localized, painful, involuntary skeletal muscle contractions of sudden onset and short duration, have been reported and were usually associated in patients receiving a relatively high cumulative dose of Cisplatin injection and with a relatively advanced symptomatic stage of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
</div>
<div class="Section">
<a name="ID53"></a><a name="section-8.9"></a><p></p>
<h2>Ocular Toxicity</h2>
<p class="First"><a name="ID54"></a><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, and cerebral <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> have been reported in patients receiving standard recommended doses of Cisplatin injection. Improvement and/or total recovery usually occurs after discontinuing Cisplatin injection. Steroids with or without mannitol have been used; however, efficacy has not been established.</p>
<p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> and altered color perception have been reported after the use of regimens with higher doses of Cisplatin injection or greater dose frequencies than recommended in the package insert. The altered color perception manifests as a loss of color discrimination, particularly in the blue-yellow axis. The only finding on funduscopic exam is irregular retinal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> of the macular area.</p>
</div>
<div class="Section">
<a name="ID55"></a><a name="section-8.10"></a><p></p>
<h2>Anaphylactic-Like Reactions</h2>
<p class="First"><a name="ID56"></a>Anaphylactic-like reactions have been reported in patients previously exposed to Cisplatin injection. The reactions consist of facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> within a few minutes of drug administration. Reactions may be controlled by intravenous epinephrine with corticosteroids and/or antihistamines as indicated. Patients receiving Cisplatin injection should be observed carefully for possible anaphylactic-like reactions and supportive equipment and medication should be available to treat such a complication.</p>
</div>
<div class="Section">
<a name="ID57"></a><a name="section-8.11"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First"><a name="ID58"></a>Transient elevations of liver enzymes, especially <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, as well as bilirubin, have been reported to be associated with Cisplatin injection administration at the recommended doses. </p>
</div>
<div class="Section">
<a name="ID59"></a><a name="section-8.12"></a><p></p>
<h2>Other Events</h2>
<p class="First"><a name="ID60"></a>Cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, elevated serum amylase, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been reported. </p>
<p>Local soft tissue toxicity has been reported following <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of Cisplatin injection. Severity of the local tissue toxicity appears to be related to the concentration of the Cisplatin injection solution. Infusion of solutions with a Cisplatin injection concentration greater than 0.5 mg/mL may result in tissue <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID61"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="ID62"></a><span class="Bold">Caution should be exercised to prevent inadvertent overdosage with Cisplatin injection. </span>Acute overdosage with this drug may result in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, ocular toxicity (including detachment of the retina), significant <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, intractable <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>. In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can occur following overdosage.</p>
<p>No proven antidotes have been established for Cisplatin injection overdosage. Hemodialysis, even when initiated four hours after the overdosage, appears to have little effect on removing platinum from the body because of Cisplatin injection’s rapid and high degree of protein binding. Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID63"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="ID64"></a>Cisplatin injection is administered by slow intravenous infusion. CISPLATIN INJECTION SHOULD NOT BE GIVEN BY RAPID INTRAVENOUS INJECTION.</p>
<p><span class="Bold">Note: Needles or intravenous sets containing aluminum parts that may come in contact with cisplatin injection should not be used for preparation or administration. Aluminum reacts with cisplatin injection, causing precipitate formation and a loss of potency.</span></p>
<div class="Section">
<a name="ID65"></a><a name="section-10.1"></a><p></p>
<h2>Metastatic Testicular Tumors</h2>
<p class="First"><a name="ID66"></a>The usual cisplatin injection dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m<span class="Sup">2</span> IV daily for 5 days per cycle.</p>
</div>
<div class="Section">
<a name="ID67"></a><a name="section-10.2"></a><p></p>
<h2>Metastatic Ovarian Tumors</h2>
<p class="First"><a name="ID68"></a>The usual Cisplatin injection dose for the treatment of metastatic ovarian tumors in combination with cyclophosphamide is 75–100 mg/m<span class="Sup">2</span> IV per cycle once every four weeks (DAY 1). </p>
<p>The dose of cyclophosphamide when used in combination with Cisplatin injection is 600 mg/m<span class="Sup">2</span> IV once every 4 weeks (DAY 1). </p>
<p>For directions for the administration of cyclophosphamide, refer to the cyclophosphamide package insert. </p>
<p>In combination therapy, Cisplatin injection and cyclophosphamide are administered sequentially. </p>
<p>As a single agent, Cisplatin injection should be administered at a dose of 100 mg/m<span class="Sup">2</span> IV per cycle once every four weeks.</p>
</div>
<div class="Section">
<a name="ID69"></a><a name="section-10.3"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span></h2>
<p class="First"><a name="ID70"></a>Cisplatin injection should be administered as a single agent at a dose of 50 to 70 mg/m<span class="Sup">2</span> IV per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients an initial dose of 50 mg/m<span class="Sup">2</span> per cycle repeated every 4 weeks is recommended. </p>
</div>
<div class="Section">
<a name="ID71"></a><a name="section-10.4"></a><p></p>
<h2>All Patients</h2>
<p class="First"><a name="ID72"></a>Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a cisplatin injection dose is recommended. The drug is then diluted in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol, and infused over a   6 to 8 hour period. If diluted solution is not to be used within 6 hours, protect solution from light. Do not dilute cisplatin injection in just 5% Dextrose Injection. Adequate hydration and urinary output must be maintained during the following 24 hours.</p>
<p>A repeat course of cisplatin injection should not be given until the serum creatinine is below 1.5 mg/100 mL, and/or the BUN is below 25 mg/100 mL. A repeat course should not be given until circulating blood elements are at an acceptable level (platelets <span class="Bold">≥</span>100,000/mm<span class="Sup">3</span>, WBC ≥4,000/mm<span class="Sup">3</span>). Subsequent doses of cisplatin injection should not be given until an audiometric analysis indicates that auditory acuity is within normal limits. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID73"></a><a name="section-11"></a><p></p>
<p class="First"><a name="ID74"></a><span class="Bold">PREPARATION OF INTRAVENOUS SOLUTIONS </span></p>
<div class="Section">
<a name="ID75"></a><a name="section-11.1"></a><p></p>
<h2>Preparation Precautions</h2>
<p class="First"><a name="ID76"></a>Caution should be exercised in handling the aqueous solution. Procedures for proper handling and disposal of anticancer drugs should be utilized. Several guidelines on this subject have been published.<span class="Sup">1-4</span> To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and IV sets containing Cisplatin injection. </p>
<p><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> associated with accidental exposure to cisplatin may occur. The use of gloves is recommended. If Cisplatin injection contacts the skin or mucosa, immediately and thoroughly wash the skin with soap and water and flush the mucosa with water. More information is available in the references listed below. </p>
</div>
<div class="Section">
<a name="ID77"></a><a name="section-11.2"></a><p></p>
<h2>Instructions for Preparation</h2>
<p class="First"><a name="ID78"></a>The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see <span class="Bold"><a href="#ID63">DOSAGE AND ADMINISTRATION</a>). </span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. </p>
<p>NOTE TO PHARMACIST: Exercise caution to prevent inadvertent Cisplatin injection overdosage. Please call prescriber if dose is greater than 100 mg/m<span class="Sup">2</span> per cycle. Aluminum and flip-off seal of vial have been imprinted with the following statement:</p>
<p><span class="Bold">CALL DR. IF DOSE &gt;100 MG/M2/CYCLE.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID79"></a><a name="section-12"></a><p></p>
<p class="First"><a name="ID80"></a><span class="Bold">STABILITY</span></p>
<p>Cisplatin injection is a sterile, multidose vial without preservatives.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] </span></p>
<p><span class="Bold">Do not refrigerate. Protect unopened container from light.</span></p>
<p>The cisplatin remaining in the amber vial following initial entry is stable for 28 days protected from light or for 7 days under fluorescent room light.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID81"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="ID82"></a>Cisplatin injection</p>
<p>NDC 67457-425-51- Each multidose vial contains 50 mg of cisplatin</p>
<p>NDC 67457-424-10 - Each multidose vial contains 100 mg of cisplatin</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID83"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. </li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html. </li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm</span>. 2006;63:1172-1193. </li>
<li>Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society. </li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID86"></a><a name="section-15"></a><p></p>
<p class="First"><a name="ID87"></a>Manufactured for:</p>
<p><span class="Bold">Mylan Institutional LLC</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:</p>
<p><span class="Bold">Agila Specialties Pvt. Ltd.</span></p>
<p>Bangalore, India</p>
<p>OCTOBER 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID88"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="50ml-carton-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb&amp;name=cisplatininjmylan-figure-02.jpg"></div>
<div class="Figure"><img alt="100 ml-carton-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64975f5d-0eca-4998-8a72-06eec98285eb&amp;name=cisplatininjmylan-figure-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CISPLATIN 		
					</strong><br><span class="contentTableReg">cisplatin injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-425</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CISPLATIN</strong> (CISPLATIN) </td>
<td class="formItem">CISPLATIN</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-425-51</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091062</td>
<td class="formItem">04/19/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CISPLATIN 		
					</strong><br><span class="contentTableReg">cisplatin injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-424</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CISPLATIN</strong> (CISPLATIN) </td>
<td class="formItem">CISPLATIN</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-424-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091062</td>
<td class="formItem">04/19/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC 
							(790384502)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Onco Therapies Limited  (676159830)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Onco Therapies Limited </td>
<td class="formItem"></td>
<td class="formItem">676159830</td>
<td class="formItem">Analysis(67457-425, 67457-424), Manufacture(67457-425, 67457-424), Sterilize(67457-425, 67457-424), Label(67457-425, 67457-424), Pack(67457-425, 67457-424)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>601e6d97-95d4-4ef8-9c70-1abdb57e3df3</div>
<div>Set id: 64975f5d-0eca-4998-8a72-06eec98285eb</div>
<div>Version: 1</div>
<div>Effective Time: 20140110</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC </div></p>
</body></html>
